Achillion Pharmaceuticals (ACHN) Upgraded by BidaskClub to Hold
BidaskClub upgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning.
ACHN has been the subject of a number of other research reports. Zacks Investment Research upgraded Achillion Pharmaceuticals from a hold rating to a buy rating and set a $4.50 target price for the company in a report on Monday, November 6th. B. Riley began coverage on Achillion Pharmaceuticals in a report on Thursday, February 8th. They issued a neutral rating and a $3.50 target price for the company. Finally, Leerink Swann restated a buy rating and issued a $5.00 target price on shares of Achillion Pharmaceuticals in a report on Monday, December 11th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $4.89.
Shares of Achillion Pharmaceuticals (ACHN) opened at $2.98 on Tuesday. The stock has a market capitalization of $410.82, a price-to-earnings ratio of -6.08 and a beta of 1.32. Achillion Pharmaceuticals has a 1-year low of $2.58 and a 1-year high of $5.66.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of Achillion Pharmaceuticals by 17.7% in the fourth quarter. BlackRock Inc. now owns 11,572,015 shares of the biopharmaceutical company’s stock worth $33,326,000 after acquiring an additional 1,736,124 shares during the last quarter. RTW Investments LP increased its position in Achillion Pharmaceuticals by 392.9% during the third quarter. RTW Investments LP now owns 7,839,766 shares of the biopharmaceutical company’s stock worth $35,201,000 after buying an additional 6,249,312 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Achillion Pharmaceuticals during the second quarter worth $20,778,000. Dimensional Fund Advisors LP increased its position in Achillion Pharmaceuticals by 75.3% during the third quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock worth $14,710,000 after buying an additional 1,407,108 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Achillion Pharmaceuticals by 128.8% during the fourth quarter. Renaissance Technologies LLC now owns 2,182,467 shares of the biopharmaceutical company’s stock worth $6,286,000 after buying an additional 1,228,492 shares during the last quarter. 76.81% of the stock is currently owned by institutional investors and hedge funds.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.